Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride.
Adults
Clinical guidelines
Fexofenadine hydrochloride
Pediatric
Second-generation antihistamines
Urticaria
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
13 May 2022
13 May 2022
Historique:
received:
14
12
2021
accepted:
11
04
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
The present narrative review provides a comprehensive update of the current knowledge on urticaria, both in adult and pediatric populations, and on the safety and efficacy of fexofenadine hydrochloride (HCl) as a treatment option. A literature search was conducted on Embase and Medline. Clinical studies published in English and published between 1999 and 2020 were selected. Although the exact pathogenesis of urticaria is not fully understood, multiple pathways of mast cell activation are discussed to explain the existence of phenotypically different clinical manifestations of urticaria. An overview of the worldwide prevalence of chronic urticaria, including disease burden and patient's quality of life is provided. The impact of urticaria on patient's life differs on the basis of whether its form is acute or chronic, but pharmacological approaches are most often needed to control the disabling symptoms. A summary of the current management of urticaria recommended by different guidelines across countries (Global; European; American; Australian; Asian; Japanese) is presented. Non-sedating, second-generation H The burden of acute and chronic urticaria is high for patients. Second generation anti-histamines such as fexofenadine HCl can help managing the symptoms.
Identifiants
pubmed: 35562767
doi: 10.1186/s13223-022-00677-z
pii: 10.1186/s13223-022-00677-z
pmc: PMC9103601
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
41Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen C, Brzoza Z, BuenseBedrikow R, Canonica GW, Church MK, Craig T, Danilycheva IV, Dressler C, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris CH, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Leslie TA, Magerl M, Mathelier-Fusade P, Meshkova RY, Metz M, Nast A, Nettis E, Oude-Elberink H, Rosumeck S, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Staubach P, Sussman G, Toubi E, Vena GA, Vestergaard C, Wedi B, Werner RN, Zhao Z, Maurer M. The EAACI/GA
doi: 10.1111/all.13397
pubmed: 29336054
Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, Zuberbier T, Keil T. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–32. https://doi.org/10.1111/all.14037 .
doi: 10.1111/all.14037
pubmed: 31494963
Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PAJ, Nasser SM. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5):631–50. https://doi.org/10.1111/j.1365-2222.2007.02678.x .
doi: 10.1111/j.1365-2222.2007.02678.x
pubmed: 17456211
Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract. 2020;8(6):1866–74. https://doi.org/10.1016/j.jaip.2020.03.030 .
doi: 10.1016/j.jaip.2020.03.030
pubmed: 32298850
Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic urticaria: a focus on pathogenesis. F1000Res. 2017;6:1095. https://doi.org/10.12688/f1000research.11546.1 .
doi: 10.12688/f1000research.11546.1
pubmed: 28751972
pmcid: 5506533
Nettis E, Foti C, Ambrifi M, Baiardini I, Bianchi L, Borghi A, Caminati M, Canonica GW, Casciaro M, Colli L, Colombo G, Corazza M, Cristaudo A, De Feo G, De Pita’ O, Di Gioacchino M, Di Leo E, Fassio F, Gangemi S, Gatta A, Hansel K, Heffler E, Incorvaia C, Napolitano M, Patruno C, Peveri S, Pigatto PD, Quecchia C, Radice A, Ramirez GA, Romita P, Rongioletti F, Rossi O, Savi E, Senna G, Triggiani M, Zucca M, Maggi E, Stingeni L. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clin Mol Allergy. 2020;18(1):8. https://doi.org/10.1186/s12948-020-00123-8 .
doi: 10.1186/s12948-020-00123-8
pubmed: 32390768
pmcid: 7201804
Poonawalla T, Kelly B. Urticaria: a review. Am J Clin Dermatol. 2009;10(1):9–21. https://doi.org/10.2165/0128071-200910010-00002 .
doi: 10.2165/0128071-200910010-00002
pubmed: 19170406
Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76(4):295–7. https://doi.org/10.2340/0001555576295297 .
doi: 10.2340/0001555576295297
pubmed: 8869688
Williams PV. Pharmacologic management of chronic urticaria in pediatric patients: the gap between guidelines and practice. Pediatr Drugs. 2020;22(1):21–8. https://doi.org/10.1007/s40272-019-00365-3 .
doi: 10.1007/s40272-019-00365-3
Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2–12. https://doi.org/10.1016/j.anai.2019.08.014 .
doi: 10.1016/j.anai.2019.08.014
pubmed: 31446134
Auyeung P, Mittag D, Hodgkin PD, Harrison LC. Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iα subunit. J Allergy Clin Immunol. 2016;138(3):761-768.e764. https://doi.org/10.1016/j.jaci.2016.04.036 .
doi: 10.1016/j.jaci.2016.04.036
pubmed: 27417022
Gonzalez-Diaz SN, Sanchez-Borges M, Rangel-Gonzalez DM, Guzman-Avilan RI, Canseco-Villarreal JI, Arias-Cruz A. Chronic urticaria and thyroid pathology. WHO J. 2020;13(3): 100101. https://doi.org/10.1016/j.waojou.2020.100101 .
doi: 10.1016/j.waojou.2020.100101
Hennino A, Bérard F, Guillot I, Saad N, Rozières A, Nicolas J-F. Pathophysiology of urticaria. Clin Rev Allergy Immunol. 2006;30(1):3–11. https://doi.org/10.1385/CRIAI:30:1:003 .
doi: 10.1385/CRIAI:30:1:003
pubmed: 16461989
Grattan CE, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy. 1991;21(6):695–704. https://doi.org/10.1111/j.1365-2222.1991.tb03198.x .
doi: 10.1111/j.1365-2222.1991.tb03198.x
pubmed: 1723343
Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599–604. https://doi.org/10.1056/nejm199306033282204 .
doi: 10.1056/nejm199306033282204
pubmed: 7683772
Sánchez J, Sánchez A, Cardona R. Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests. Allergy Asthma Immunol Res. 2019;11(1):29–42.
doi: 10.4168/aair.2019.11.1.29
Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, Maurer M. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876–82. https://doi.org/10.1016/j.jaci.2017.10.035 .
doi: 10.1016/j.jaci.2017.10.035
pubmed: 29208545
Hatada Y, Kashiwakura J, Hayama K, Fujisawa D, Sasaki-Sakamoto T, Terui T, Ra C, Okayama Y. Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients. Int Arch Allergy Immunol. 2013;161(Suppl 2):154–8. https://doi.org/10.1159/000350388 .
doi: 10.1159/000350388
pubmed: 23711867
Zheng W, Wang J, Zhu W, Xu C, He S. Upregulated expression of substance P in basophils of the patients with chronic spontaneous urticaria: induction of histamine release and basophil accumulation by substance P. Cell Biol Toxicol. 2016;32(3):217–28. https://doi.org/10.1007/s10565-016-9330-4 .
doi: 10.1007/s10565-016-9330-4
pubmed: 27147256
Metz M, Krull C, Hawro T, Saluja R, Groffik A, Stanger C, Staubach P, Maurer M. Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. J Investig Dermatol. 2014;134(11):2833–6. https://doi.org/10.1038/jid.2014.226 .
doi: 10.1038/jid.2014.226
pubmed: 24844859
Cookson H, Grattan C. An update on mast cell disorders. Clin Med (Lond). 2016;16(6):580–3. https://doi.org/10.7861/clinmedicine.16-6-580 .
doi: 10.7861/clinmedicine.16-6-580
Boyden SE, Desai A, Cruse G, Young ML, Bolan HC, Scott LM, Eisch AR, Long RD, Lee CC, Satorius CL, Pakstis AJ, Olivera A, Mullikin JC, Chouery E, Megarbane A, Medlej-Hashim M, Kidd KK, Kastner DL, Metcalfe DD, Komarow HD. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med. 2016;374(7):656–63. https://doi.org/10.1056/NEJMoa1500611 .
doi: 10.1056/NEJMoa1500611
pubmed: 26841242
pmcid: 4782791
Farinazzo E, Dianzani C, Zalaudek I, Conforti C, Grabbe S, Goldust M. Synthesis of the data on COVID-19 skin manifestations: underlying mechanisms and potential outcomes. Clin Cosmet Investig Dermatol. 2021;14:991–7. https://doi.org/10.2147/ccid.S325552 .
doi: 10.2147/ccid.S325552
pubmed: 34385830
pmcid: 8354337
Alam M, Lewis W, Harp J, Steele K, Rosenbach M, Micheletti RG. Cutaneous manifestations of COVID-19: characteristics, pathogenesis, and the role of dermatology in the pandemic. Cutis. 2021;107(4):209–15. https://doi.org/10.12788/cutis.0230 .
doi: 10.12788/cutis.0230
pubmed: 34096848
Klimach A, Evans J, Stevens J, Creasey N. Rash as a presenting complaint in a child with COVID-19. Pediatr Dermatol. 2020;37(5):966–7. https://doi.org/10.1111/pde.14257 .
doi: 10.1111/pde.14257
pubmed: 32524630
Navaeifar MR, PoudinehGhazaghi M, Shahbaznejad L, Rouhanizadeh H, Abutalebi M, RanjbarVarandi M, Rezai MS. Fever with rash is one of the first presentations of COVID-19 in children: a case report. Int Med Case Rep J. 2020;13:335–40. https://doi.org/10.2147/imcrj.S262935 .
doi: 10.2147/imcrj.S262935
pubmed: 32821174
pmcid: 7425085
Criado PR, Pagliari C, Criado RFJ, Marques GF, Belda W Jr. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020;33(6): e14068. https://doi.org/10.1111/dth.14068 .
doi: 10.1111/dth.14068
pubmed: 32713127
Algaadi SA. Urticaria and COVID-19: a review. Dermatol Ther. 2020. https://doi.org/10.1111/dth.14290 .
doi: 10.1111/dth.14290
pubmed: 32902087
Abuelgasim E, Dona ACM, Sondh RS, Harky A. Management of urticaria in COVID-19 patients: a systematic review. Dermatol Ther. 2021. https://doi.org/10.1111/dth.14328 .
doi: 10.1111/dth.14328
pubmed: 32986289
Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, Navarro Fernández I, Ruiz-Villaverde R, Falkenhain-López D, Llamas Velasco M, García-Gavín J, Baniandrés O, González-Cruz C, Morillas-Lahuerta V, Cubiró X, FiguerasNart I, Selda-Enriquez G, Romaní J, Fustà-Novell X, Melian-Olivera A, RonceroRiesco M, Burgos-Blasco P, Sola Ortigosa J, Feito Rodriguez M, García-Doval I. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7. https://doi.org/10.1111/bjd.19163 .
doi: 10.1111/bjd.19163
pubmed: 32348545
pmcid: 7267236
Shahidi Dadras M, Rakhshan A, Diab R, Abdollahimajd F. SARS-CoV-2 infection as a potential triggering factor for urticarial vasculitis during pregnancy: a case report. Clin Case Rep. 2021;9(6): e04323. https://doi.org/10.1002/ccr3.4323 .
doi: 10.1002/ccr3.4323
pubmed: 34194805
pmcid: 8223884
Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(10):e568–70. https://doi.org/10.1111/jdv.16721 .
doi: 10.1111/jdv.16721
pubmed: 32525251
pmcid: 7307033
Quintana-Castanedo L, Feito-Rodríguez M, Valero-López I, Chiloeches-Fernández C, Sendagorta-Cudós E, Herranz-Pinto P. Urticarial exanthem as early diagnostic clue for COVID-19 infection. JAAD Case Rep. 2020;6(6):498–9. https://doi.org/10.1016/j.jdcr.2020.04.026 .
doi: 10.1016/j.jdcr.2020.04.026
pubmed: 32352022
pmcid: 7189196
Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(6):e244–5. https://doi.org/10.1111/jdv.16472 .
doi: 10.1111/jdv.16472
pubmed: 32294273
pmcid: 7262133
Ahouach B, Harent S, Ullmer A, Martres P, Bégon E, Blum L, Tess O, Bachmeyer C. Cutaneous lesions in a patient with COVID-19: are they related? Br J Dermatol. 2020;183(2):e31–e31. https://doi.org/10.1111/bjd.19168 .
doi: 10.1111/bjd.19168
pubmed: 32353170
pmcid: 7267646
Falkenhain-López D, Sánchez-Velázquez A, López-Valle A, Ortiz-Frutos FJ. SARS-Coronavirus-2 and acute urticaria. Int J Dermatol. 2020;59(7):867–8. https://doi.org/10.1111/ijd.14950 .
doi: 10.1111/ijd.14950
pubmed: 32441802
pmcid: 7280648
Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7): e236981. https://doi.org/10.1136/bcr-2020-236981 .
doi: 10.1136/bcr-2020-236981
pubmed: 32641443
pmcid: 7342472
Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, Harp J, Takeshita J, French LE, Lim HW, Thiers BH, Hruza GJ, Fox LP. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118–29. https://doi.org/10.1016/j.jaad.2020.06.1016 .
doi: 10.1016/j.jaad.2020.06.1016
pubmed: 32622888
pmcid: 7331510
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212–3. https://doi.org/10.1111/jdv.16387 .
doi: 10.1111/jdv.16387
pubmed: 32215952
De Giorgi V, Recalcati S, Jia Z, Chong W, Ding R, Deng Y, Scarfi F, Venturi F, Trane L, Gori A, Silvestri F, Gao XH, Lotti T. Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): a prospective study from China and Italy. J Am Acad Dermatol. 2020;83(2):674–5. https://doi.org/10.1016/j.jaad.2020.05.073 .
doi: 10.1016/j.jaad.2020.05.073
pubmed: 32442696
pmcid: 7235557
Nagashima S, Dutra AA, Arantes MP, Zeni RC, Klein CK, de Oliveira FC, Piper GW, Brenny ID, Pereira MRC, Stocco RB, Martins APC, de Castro EM, Vaz de Paula CB, Amaral ANM, Machado-Souza C, Baena CP, Noronha L. COVID-19 and lung mast cells: the Kallikrein-Kinin activation pathway. Int J Mol Sci. 2022;23(3):1714. https://doi.org/10.3390/ijms23031714 .
doi: 10.3390/ijms23031714
pubmed: 35163636
pmcid: 8836064
McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6): 102537. https://doi.org/10.1016/j.autrev.2020.102537 .
doi: 10.1016/j.autrev.2020.102537
pubmed: 32251717
pmcid: 7195002
Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, Harp J, Nuovo G. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141–50. https://doi.org/10.1111/bjd.19415 .
doi: 10.1111/bjd.19415
pubmed: 32779733
pmcid: 7405151
Maxim E, Aksut C, Tsoi D, Dellavalle R. Global burden of urticaria: insights from the 2016 Global Burden of Disease Study. J Am Acad Dermatol. 2018;79(3):567–9. https://doi.org/10.1016/j.jaad.2018.02.026 .
doi: 10.1016/j.jaad.2018.02.026
pubmed: 29438758
pmcid: 6119764
Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, Fomina D, Galvàn CA, Godse K, Grattan C, Hide M, Katelaris CH, Khoshkhui M, Kocatürk E, Kulthanan K, Medina I, Nasr I, Peter J, Staubach P, Wang L, Weller K, Maurer M. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021. https://doi.org/10.1111/bjd.19561 .
doi: 10.1111/bjd.19561
pubmed: 32956489
Huang Y, Xiao Y, Zhang X, Li J, Chen X, Shen M. A meta-analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety. Front Med (Lausanne). 2020;7:39–39. https://doi.org/10.3389/fmed.2020.00039 .
doi: 10.3389/fmed.2020.00039
Konstantinou GN, Konstantinou GN. Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy. 2019;9(1):42. https://doi.org/10.1186/s13601-019-0278-3 .
doi: 10.1186/s13601-019-0278-3
pubmed: 31462988
pmcid: 6706894
Hergüner S, Kiliç G, Karakoç S, Tamay Z, Tüzün U, Güler N. Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. Br J Dermatol. 2011;164(6):1342–7. https://doi.org/10.1111/j.1365-2133.2010.10138.x .
doi: 10.1111/j.1365-2133.2010.10138.x
pubmed: 21083542
Hsieh P-Y, Chang C-Y, Chou C-C, Lin Y-R, Chen C-Y. Urticaria in adolescence increases the risk of developing new-onset depression: a database study. JACME. 2014;4(3):120–6. https://doi.org/10.1016/j.jacme.2014.06.002 .
doi: 10.1016/j.jacme.2014.06.002
Staubach P, Dechene M, Metz M, Magerl M, Siebenhaar F, Weller K, Zezula P, Eckhardt-Henn A, Maurer M. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011;91(5):557–61. https://doi.org/10.2340/00015555-1109 .
doi: 10.2340/00015555-1109
pubmed: 21597672
Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35–9. https://doi.org/10.1001/archdermatol.2007.5 .
doi: 10.1001/archdermatol.2007.5
pubmed: 18209166
Balp M-M, Abuzakouk M, Berard F, Canonica G.W, Gimenez-Arnau A, Hollis K, Khalil S, Knulst A.C, Lacour J-P, Lynde C, Marsland A, Maurer M, McBride D, Nakonechna A, Ortiz de Frutoz FJ, Oude Elberink J.N.G, Proctor C, Sussman G, Weller K, Grattan C (2016) Comparison of direct healthcare costs associated with chronic spontaneous/idiopathic urticaria in 7 countries: Results from th ASSURE-CSU study Paper presented at the ISPOR Vienna, 29 October.
Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, Grattan C, Hollis K, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Nakonechna A, Ortiz de Frutos J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Wolin D, Balp MM. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–16. https://doi.org/10.1111/all.13209 .
doi: 10.1111/all.13209
pubmed: 28543019
Sánchez-Borges M, González-Díaz SN, Ortega Martel JA, Rojo I, IJ AZ (2020) Management of severe chronic urticaria: current and future therapies. Clin Trials 10(6)
Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, Sheikh J, Weldon D, Zuraw B, Bernstein DI, Blessing-Moore J, Cox L, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–7. https://doi.org/10.1016/j.jaci.2014.02.036 .
doi: 10.1016/j.jaci.2014.02.036
pubmed: 24766875
Chow SKW. Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy. 2012;2(2):149–60. https://doi.org/10.5415/apallergy.2012.2.2.149 .
doi: 10.5415/apallergy.2012.2.2.149
pubmed: 22701866
pmcid: 3345329
Perera E, Sinclair R. Evaluation, diagnosis and management of chronic urticaria. Aust Fam Phys. 2014;43:621–5.
Hide M. Japanese guidelines for diagnosis and treatment of urticaria, 2018. Arerugi [Allergy]. 2018;67(10):1394–8. https://doi.org/10.15036/arerugi.67.1394 .
doi: 10.15036/arerugi.67.1394
Godse K, Patil A, Godse G. Urticaria and its management in the context of coronavirus disease-19 (COVID-19). IP Indian J Clin Exp Dermatol. 2020;6(2):102–4. https://doi.org/10.18231/j.ijced.2020.022 .
doi: 10.18231/j.ijced.2020.022
Simons FE, Simons KJ. H1 antihistamines: current status and future directions. WHO J. 2008;1(9):145–55. https://doi.org/10.1097/WOX.0b013e318186fb3a .
doi: 10.1097/WOX.0b013e318186fb3a
Fitzsimons R, Van Der Poel LA, Thornhill W, Du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child. 2015;100(3):122–31. https://doi.org/10.1136/archdischild-2013-304446 .
doi: 10.1136/archdischild-2013-304446
AdisInsight Drugs Fexofenadine - sanofi-aventis. AdisInsight Drugs. https://adisinsight.springer.com/drugs/800006524 . Accessed February 2021
Sanchez J, Zakzuk J, Cardona R. Prediction of five antihistamines efficacy in chronic spontaneous urticaria with conventional or higher doses, based on histamine wheal diameter change. Allergy. 2015;70:10. https://doi.org/10.1111/all.12715 .
doi: 10.1111/all.12715
Huang CZ, Jiang ZH, Wang J, Luo Y, Peng H. Antihistamine effects and safety of fexofenadine: a systematic review and meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019. https://doi.org/10.1186/s40360-019-0363-1 .
doi: 10.1186/s40360-019-0363-1
pubmed: 31783781
pmcid: 6884918
Maciel-Guerra H, Penha MÁ, Jorge MFS, Libório RdS, Carrijo ACNDA, Parise-Fortes MR, Miot HA. Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil. An Bras Dermatol. 2018;93(2):233–7. https://doi.org/10.1590/abd1806-4841.20186807 .
doi: 10.1590/abd1806-4841.20186807
pubmed: 29723372
pmcid: 5916396
Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. Allergy Asthma Proc. 2007;28(1):67–73.
doi: 10.2500/aap.2007.28.2895
Tanizaki H, Ikoma A, Fukuoka M, Miyachi Y, Kabashima K. Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. Int Arch Allergy Immunol. 2012;158(2):191–5. https://doi.org/10.1159/000330663 .
doi: 10.1159/000330663
pubmed: 22286689
Purohit A, N’Gom AS, Deslandes B, Pauli G, Frossard N. Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Ann Allergy Asthma Immunol. 2004;93(6):562–7.
doi: 10.1016/S1081-1206(10)61264-1
Paul E, Berth-Jones J, Ortonne JP, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat. 1998;9(3):143–9. https://doi.org/10.3109/09546639809160545 .
doi: 10.3109/09546639809160545
Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005;94(6):662–9. https://doi.org/10.1016/s1081-1206(10)61325-7 .
doi: 10.1016/s1081-1206(10)61325-7
pubmed: 15984599
Fouad M, Ragab M. Effectiveness and safety of fexofenadine in chronic idiopathic urticaria: open-label noncomparative study in daily practice. Egypt J Dermatol Venerol. 2017;37(2):43–8. https://doi.org/10.4103/ejdv.ejdv_38_16 .
doi: 10.4103/ejdv.ejdv_38_16
Iriarte Sotés P, Armisén M, Usero-Bárcena T, Rodriguez Fernández A, Otero Rivas M, Gonzalez MT, Meijide Calderón A, Veleiro B (2020) Up-dosing antihistamines in chronic spontaneous urticaria: efficacy and safety. A systematic review of the literature. J Investig Allergol Clin Immunol. https://doi.org/10.18176/jiaci.0649 .
Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol. 2000;43(1):24–30.
doi: 10.1067/mjd.2000.104680
Spector SL, Shikiar R, Harding G, Meeves S, Leahy MJ. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis. 2007;79(2):157–62.
pubmed: 17388220
Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517–22.
doi: 10.1016/S1081-1206(10)62515-X
Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104(5):1071–8. https://doi.org/10.1016/s0091-6749(99)70091-6 .
doi: 10.1016/s0091-6749(99)70091-6
pubmed: 10550755
Olasińska-Wiśniewska A, Olasiński J, Grajek S. Cardiovascular safety of antihistamines. Postepy Dermatol Alergol. 2014;31(3):182–6. https://doi.org/10.5114/pdia.2014.43191 .
doi: 10.5114/pdia.2014.43191
pubmed: 25097491
pmcid: 4112269
Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(Suppl 3):212–6. https://doi.org/10.1046/j.1365-2222.1999.0290s3212.x .
doi: 10.1046/j.1365-2222.1999.0290s3212.x
pubmed: 10444240
Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. British Br J Clin Pharmacol. 1999;48(2):200–6. https://doi.org/10.1046/j.1365-2125.1999.00993.x .
doi: 10.1046/j.1365-2125.1999.00993.x
Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy. 2002;32(1):133–9. https://doi.org/10.1046/j.0022-0477.2001.01245.x .
doi: 10.1046/j.0022-0477.2001.01245.x
pubmed: 12002730
Hiraoka K, Tashiro M, Grobosch T, Maurer M, Oda K, Toyohara J, Ishii K, Ishiwata K, Yanai K. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin Drug Saf. 2015;14(2):199–206. https://doi.org/10.1517/14740338.2015.989831 .
doi: 10.1517/14740338.2015.989831
pubmed: 25466429
Klyucharova A, Mendelevich V, Skorohodkina O. Effect of II generation antihistamines on cognitive functions of chronic urticaria patients. Allergy. 2012;67:496. https://doi.org/10.1111/all.12037 .
doi: 10.1111/all.12037
Isomura T, Kono T, Hindmarch I, Kikuchi N, Murakami A, Inuzuka K, Kawana S. Central nervous system effects of the second-generation antihistamines marketed in Japan—review of inter-drug differences using the proportional impairment ratio (PIR). PLoS ONE. 2014;9(12): e114336. https://doi.org/10.1371/journal.pone.0114336 .
doi: 10.1371/journal.pone.0114336
pubmed: 25501360
pmcid: 4264760
Inami A, Matsuda R, Grobosch T, Komamura H, Takeda K, Yamada Y, Miyake M, Hiraoka K, Maurer M, Yanai K, Tashiro M. A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers. Hum Psychopharmacol Clin Exp. 2016;31(3):167–77. https://doi.org/10.1002/hup.2524 .
doi: 10.1002/hup.2524
Bower EA, Moore JL, Moss M, Selby KA, Austin M, Meeves S. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med. 2003;74(2):145–52.
pubmed: 12602446
Church MK, Weller K, Stock P, Maurer M. Chronic spontaneous urticaria in children: itching for insight. Pediatr Allergy Immunol. 2011;22(1 Pt 1):1–8. https://doi.org/10.1111/j.1399-3038.2010.01120.x .
doi: 10.1111/j.1399-3038.2010.01120.x
pubmed: 21261741
Pite H, Wedi B, Borrego LM, Kapp A, Raap U. Management of childhood urticaria: current knowledge and practical recommendations. Acta Derm Venereol. 2013;93(5):500–8. https://doi.org/10.2340/00015555-1573 .
doi: 10.2340/00015555-1573
pubmed: 23546182
Milgrom H, Kittner B, Lanier R, Hampel FC. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol. 2007;99(4):358–63. https://doi.org/10.1016/s1081-1206(10)60553-4 .
doi: 10.1016/s1081-1206(10)60553-4
pubmed: 17941284
Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79(5):443–8. https://doi.org/10.1016/s1081-1206(10)63041-4 .
doi: 10.1016/s1081-1206(10)63041-4
pubmed: 9396979
Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(4):354–61. https://doi.org/10.1016/s1081-1206(10)61682-1 .
doi: 10.1016/s1081-1206(10)61682-1
pubmed: 14582814
Meltzer EO, Scheinmann P, Rosado Pinto JE, Bachert C, Hedlin G, Wahn U, Finn AF Jr, Ruuth E. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis—a pooled analysis of three studies. Pediatr Allergy Immunol. 2004;15(3):253–60. https://doi.org/10.1111/j.1399-3038.2004.00167.x .
doi: 10.1111/j.1399-3038.2004.00167.x
pubmed: 15209959
Segall N, Grubbe RE, Levy AL, Maloney MJ, Nayak AS, Kittner B, Quesada JT. Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. Allergy Asthma Proc. 2008;29(4):380–5. https://doi.org/10.2500/aap.2008.29.3136 .
doi: 10.2500/aap.2008.29.3136
pubmed: 18702885